← Leaderboards
Stanley R Hamilton
Johns Hopkins University
$26,840,413
Attributed
$47,570,683
Total exposure
12
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,570,683 · 12
By mechanism
U24$36,939,788 · 1
P30$3,972,521 · 3
R01$3,817,304 · 2
P01$1,430,572 · 1
R21$753,015 · 2
P50$657,483 · 3
Top collaborators
- Ignacio I. Wistuba12 shared
- Scott Kopetz7 shared
- George A. Calin2 shared
- Ramana V Davuluri2 shared
- Wei Zhang2 shared
- Scott D. Jewell1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Thomas W Kensler$20,869,769
- Yuesheng Zhang$12,984,679
- Lawrence S. Wissow$8,571,534
- Michael Alan Trush$4,292,939
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsClinical ResearchBaseClinical TrialsTissuesProgramsMethodologyPathologyLaboratoriesServicesResearch PersonnelSpecimenProteinsFutureDatabasesHeadFundingResourcesMedicineClinicSitePathologistBloodCancer Prevention
Grant awards (59)
ECOG-ACRIN Biospecimen Bank to Support NCTN$4,113,603
U24 · FY2025 · CA
Research Pathology$200,397
P30 · FY2025 · CA · contact PI
ECOG-ACRIN Biospecimen Bank to Support NCTN$3,940,623
U24 · FY2024 · CA
Research Pathology$198,039
P30 · FY2024 · CA · contact PI
ECOG-ACRIN Biospecimen Bank to Support NCTN$4,417,245
U24 · FY2023 · CA
Research Pathology$154,811
P30 · FY2023 · CA · contact PI
ECOG-ACRIN Biospecimen Bank to Support NCTN$4,035,965
U24 · FY2022 · CA
ECOG-ACRIN Biospecimen Bank to Support NCTN$4,122,671
U24 · FY2021 · CA
ECOG-ACRIN Biospecimen Bank to Support NCTN$2,515,975
U24 · FY2020 · CA
ECOG-ACRIN Biorepositories to Support NCTN$891,547
U24 · FY2020 · CA
ECOG-ACRIN Biorepositories to Support NCTN$2,950,520
U24 · FY2019 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$612,599
R01 · FY2019 · CA
ECOG-ACRIN Biorepositories to Support NCTN$2,218,340
U24 · FY2018 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$616,538
R01 · FY2018 · CA
ECOG-ACRIN Biorepositories to Support NCTN$599,831
U24 · FY2018 · CA
ECOG-ACRIN Biorepositories to Support NCTN$2,602,733
U24 · FY2017 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$623,897
R01 · FY2017 · CA
ECOG-ACRIN Biorepositories to Support NCTN$2,245,660
U24 · FY2016 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$659,613
R01 · FY2016 · CA
ECOG-ACRIN Biorepositories to Support NCTN$2,285,075
U24 · FY2015 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$653,792
R01 · FY2015 · CA
Research Histopathology$396,134
P30 · FY2012 · CA · contact PI
Tissue Procurement and Banking Facility$310,666
P30 · FY2012 · CA · contact PI
Identification of microRNAs as blood-based markers for colorectal cancer$171,825
R21 · FY2012 · CA
Tissue Procurement and Banking Facility$2,882
P30 · FY2012 · CA · contact PI
Research Histopathology$2,882
P30 · FY2012 · CA · contact PI
Research Histopathology$403,675
P30 · FY2011 · CA · contact PI
Tissue Procurement and Banking Facility$317,533
P30 · FY2011 · CA · contact PI
Identification of microRNAs as blood-based markers for colorectal cancer$206,190
R21 · FY2011 · CA
Research Histopathology$419,985
P30 · FY2010 · CA · contact PI
Tissue Procurement and Banking Facility$331,049
P30 · FY2010 · CA · contact PI
MicroRNAs and other non-coding RNAs in Colorectal Metastasis$315,833
R01 · FY2010 · CA
Research Histopathology$422,026
P30 · FY2009 · CA · contact PI
MicroRNAs and other non-coding RNAs in Colorectal Metastasis$335,032
R01 · FY2009 · CA
Tissue Procurement and Banking Facility$333,366
P30 · FY2009 · CA · contact PI
Advanced Adenomas and Serrated Adenomas as precursors$325,319
P01 · FY2009 · CA · contact PI
Advanced Adenomas and Serrated Adenomas as precursors$317,648
P01 · FY2008 · CA · contact PI
Research Histopathology$267,611
P30 · FY2008 · CA · contact PI
Tissue Procurement and Banking Facility$211,465
P30 · FY2008 · CA · contact PI
Advanced Adenomas and Serrated Adenomas as precursors$316,705
P01 · FY2007 · CA · contact PI
Advanced Adenomas and Serrated Adenomas as precursors$202,923
P01 · FY2006 · CA · contact PI
Advanced Adenomas and Serrated Adenomas as precursors$267,977
P01 · FY2005 · CA
AGENTS AND MECHANISMS OF TUMOR PREVENTION IN THE MIN MODEL OF FAP$0
P50 · FY2002 · CA
CORE--HUMAN TISSUE RESOURCE AND LOGISTICS$0
P50 · FY2002 · CA
MOLECULAR MARKERS FOR METASTASIS OF COLORECTAL CANCER$0
P50 · FY2002 · CA
MOLECULAR MARKERS IN ESOPHAGEAL ADENOCARCINOMA$187,500
R21 · FY2001 · CA
AGENTS AND MECHANISMS OF TUMOR PREVENTION IN THE MIN MODEL OF FAP$0
P50 · FY2001 · CA
CORE--HUMAN TISSUE RESOURCE AND LOGISTICS$0
P50 · FY2001 · CA
CORE--HUMAN TISSUE RESOURCE AND LOGISTICS$0
P50 · FY2001 · CA
CORE--HUMAN TISSUE RESOURCE AND LOGISTICS$0
P50 · FY2001 · CA
MOLECULAR MARKERS FOR METASTASIS OF COLORECTAL CANCER$0
P50 · FY2001 · CA
MOLECULAR MARKERS FOR METASTASIS OF COLORECTAL CANCER$0
P50 · FY2001 · CA
MOLECULAR MARKERS FOR METASTASIS OF COLORECTAL CANCER$0
P50 · FY2001 · CA
AGENTS AND MECHANISMS OF TUMOR PREVENTION IN THE MIN MODEL OF FAP$0
P50 · FY2001 · CA
AGENTS AND MECHANISMS OF TUMOR PREVENTION IN THE MIN MODEL OF FAP$0
P50 · FY2001 · CA
MOLECULAR MARKERS FOR METASTASIS OF COLORECTAL CANCER$219,161
P50 · FY2000 · CA
AGENTS AND MECHANISMS OF TUMOR PREVENTION IN THE MIN MODEL OF FAP$219,161
P50 · FY2000 · CA
CORE--HUMAN TISSUE RESOURCE AND LOGISTICS$219,161
P50 · FY2000 · CA
MOLECULAR MARKERS IN ESOPHAGEAL ADENOCARCINOMA$187,500
R21 · FY2000 · CA